MX2018015759A - Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. - Google Patents

Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.

Info

Publication number
MX2018015759A
MX2018015759A MX2018015759A MX2018015759A MX2018015759A MX 2018015759 A MX2018015759 A MX 2018015759A MX 2018015759 A MX2018015759 A MX 2018015759A MX 2018015759 A MX2018015759 A MX 2018015759A MX 2018015759 A MX2018015759 A MX 2018015759A
Authority
MX
Mexico
Prior art keywords
vortioxetine
composition
steady
antidepressant effect
fast onset
Prior art date
Application number
MX2018015759A
Other languages
English (en)
Inventor
Bang-Andersen Benny
Krøjer Søby Karina
Sanchez Morillo Connie
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59239917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018015759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2018015759A publication Critical patent/MX2018015759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un régimen de dosificación que comprende la administración simultánea de dos composiciones farmacéuticas, en donde la primera composición farmacéutica es una composición que comprende vortioxetina o una sal farmacéuticamente aceptable de la misma para una administración oral una vez al día, y la segunda composición farmacéutica es una composición que comprende vortioxetina o una sal farmacéuticamenteaceptable de la misma que, junto con la primera composición, logra rápidamente un nivel en plasma de estado estacionario de vortioxetina en el paciente, nivel en plasma de estado estacionario que es esencialmente elmismo que el nivel en plasma de estado estacionario de vortioxetina logrado por la administración al paciente de la primera composición sola.
MX2018015759A 2016-07-01 2017-06-28 Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. MX2018015759A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357722P 2016-07-01 2016-07-01
PCT/EP2017/065958 WO2018002115A1 (en) 2016-07-01 2017-06-28 Vortioxetine dosing regimes for fast onset of antidepressant effect

Publications (1)

Publication Number Publication Date
MX2018015759A true MX2018015759A (es) 2019-03-21

Family

ID=59239917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015759A MX2018015759A (es) 2016-07-01 2017-06-28 Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.

Country Status (17)

Country Link
US (4) US9820984B1 (es)
EP (1) EP3478289A1 (es)
JP (1) JP2019524682A (es)
KR (1) KR20190025556A (es)
CN (1) CN109310691A (es)
AU (1) AU2017288456A1 (es)
BR (1) BR112018003930A2 (es)
CA (1) CA3026728A1 (es)
CL (1) CL2018003707A1 (es)
CO (1) CO2018013792A2 (es)
IL (1) IL263584A (es)
MA (1) MA45532A (es)
MX (1) MX2018015759A (es)
RU (1) RU2018144248A (es)
SG (1) SG11201810644TA (es)
TW (1) TW201806599A (es)
WO (1) WO2018002115A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9820984B1 (en) * 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP2439201B1 (en) 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
EA016054B1 (ru) 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
MX2011011119A (es) 2009-04-24 2011-11-04 Lundbeck & Co As H Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina.
EP2470166B1 (en) 2009-08-24 2013-08-14 H. Lundbeck A/S New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
US9133144B2 (en) 2012-01-03 2015-09-15 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
WO2014090929A1 (en) 2012-12-13 2014-06-19 H. Lundbeck A/S Compositions comprising vortioxetine and donepezil
MA38338B1 (fr) 2013-02-22 2018-10-31 H Lundbeck As Procédé de fabrication de vortioxétine
US10376506B2 (en) * 2013-12-20 2019-08-13 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
US9820984B1 (en) * 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect

Also Published As

Publication number Publication date
US20180153881A1 (en) 2018-06-07
BR112018003930A2 (pt) 2018-09-25
US9913839B2 (en) 2018-03-13
MA45532A (fr) 2019-05-08
CN109310691A (zh) 2019-02-05
KR20190025556A (ko) 2019-03-11
US20200030319A1 (en) 2020-01-30
CL2018003707A1 (es) 2019-02-15
TW201806599A (zh) 2018-03-01
US9820984B1 (en) 2017-11-21
AU2017288456A1 (en) 2018-12-13
SG11201810644TA (en) 2018-12-28
CO2018013792A2 (es) 2019-01-18
CA3026728A1 (en) 2018-01-04
RU2018144248A (ru) 2020-08-03
US10258617B2 (en) 2019-04-16
IL263584A (en) 2019-01-31
US20180000815A1 (en) 2018-01-04
WO2018002115A1 (en) 2018-01-04
EP3478289A1 (en) 2019-05-08
JP2019524682A (ja) 2019-09-05

Similar Documents

Publication Publication Date Title
MX2021001982A (es) Administracion local y concomitante de nanoportadores sinteticos, tolerogenicos para reducir la hipersensibilidad tipo i y tipo iv.
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
BR112017001968A2 (pt) embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
CO2017002682A2 (es) Composiciones y métodos para recubrimientos cannabinoides para uso en la entrega de fármacos
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
WO2012145575A3 (en) Therapy for leukemia
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
MX2018015759A (es) Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MX358211B (es) Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.